Scroll To Top

Squibb, Medivir join HIV drug pact

Squibb, Medivir join HIV drug pact

Drugmaker Bristol-Myers Squibb Co. and Swedish drug developer Medivir AB said Wednesday they entered a collaboration to develop and sell a new HIV treatment.

Under the agreement, Princeton, N.J.-based Bristol-Myers will pay Medivir $7.5 million up front to help develop Medivir's MIV-170 drug candidate. Medivir could also receive up to $97 million in milestone payments and additional royalties on sales of the treatment if it makes it to market.

Bristol-Myers would get all world rights to MIV-170 except for rights in Medivir's Nordic region. (AP)

Advocate Magazine - KehlaniAdvocate Channel Promotion

From our Sponsors

Most Popular

Be sure to follow Advocate on your favorite social platforms!


Want more news, top stories, and videos? Check out the all NEW Advocate Channel!
Your 24/7 streaming source for equality news and lifestyle trends.
Click this link right now:

Latest Stories